Clinical Trial Update: China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD [Phase 4]

View source ↗

Summary

Phase 4 post-approval commitment study of avalglucosidase alfa for Pompe disease, currently recruiting in China in participants with infantile-onset Pompe disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Avalglucosidase alfa (avalglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II, Pompe's Disease | Phase 4 | Status: RECRUITING